ALTEOGEN Inc. Stock

Equities

A196170

KR7196170005

Pharmaceuticals

End-of-day quote Korea S.E. 18:00:00 2024-07-18 EDT 5-day change 1st Jan Change
271,500 KRW +3.23% Intraday chart for ALTEOGEN Inc. -0.37% +175.63%

Financials

Sales 2024 * 78.73B 56.69M 77.79M Sales 2025 * 170B 122M 168M Capitalization 14,423B 10.38B 14.25B
Net income 2024 * 7B 5.04M 6.92M Net income 2025 * 50B 36M 49.4M EV / Sales 2024 * 183 x
Net cash position 2024 * 36.8B 26.5M 36.36M Net cash position 2025 * 59.2B 42.62M 58.49M EV / Sales 2025 * 84.7 x
P/E ratio 2024 *
2,011 x
P/E ratio 2025 *
282 x
Employees 128
Yield 2024 *
-
Yield 2025 *
-
Free-Float 68.57%
More Fundamentals * Estimated data
Dynamic Chart
Alteogen Inc. Receives Ministry of Food and Drug Safety Approval for Tergase® CI
Alteogen Inc. Announces Clinical Trial of Tergase Showed Zero Incidence of ADA CI
ALTEOGEN Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
ALTEOGEN Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
ALTEOGEN Inc. Enters into an Exclusive License Agreement to Develop and Commercialize Biosimilar Products Enabled by its Hybrozyme Technology CI
Alteogen Inc. Announces Completion of Phase 1 Clinical Trial of Aflibercept Biosimilar in Wet AMD Patients CI
Alteogen Enters Into Exclusive License Agreement With Intas to Develop and Commercialize Two Products Enabled by Its Hybrozyme™ Technology CI
ALTEOGEN Inc. announced that it has received KRW 74.999925 billion in funding from SG Core Co., Ltd. CI
ALTEOGEN Inc. announced that it expects to receive KRW 74.999925 billion in funding from SG Core Co., Ltd. CI
ALTEOGEN Inc. announced that it has received KRW 29.9992875 billion in funding from Shinhan Bank, SL Investment, Future Growth Strategy Bio New Technology Investment Fund, Korea Investment Holdings Co., Ltd., Korea Securities Finance Corporation CI
ALTEOGEN Inc. announced that it expects to receive KRW 29.9992875 billion in funding from Shinhan Bank, SL Investment, Future Growth Strategy Bio New Technology Investment Fund, Korea Investment Holdings Co., Ltd., Korea Securities Finance Corporation CI
ALTEOGEN Inc.(KOSDAQ:A196170) added to FTSE All-World Index CI
Alteogen Enters into a Global License Agreement with a Top Ten Pharmaceutical Company for Use of Its Hybrozyme Technology to Enable Subcutaneous Administration of Biologic Products CI
ALTEOGEN Inc. Presents the First-In-Human Data on Alt-P7, A Her2-Targeting Antibody-Drug Conjugate At ASCO 2020 CI
Alteogen Enters into a Non-exclusive License Agreement with a Global Pharmaceutical Company for Use of its Hybrozyme™ Technology to Enable Subcutaneous Administration of Biologic Products CI
More news
1 day+3.23%
1 week-0.37%
Current month-3.21%
1 month+4.62%
3 months+61.22%
6 months+259.13%
Current year+175.63%
More quotes
1 week
260 000.00
Extreme 260000
283 500.00
1 month
251 000.00
Extreme 251000
298 500.00
Current year
70 500.00
Extreme 70500
298 500.00
1 year
40 500.00
Extreme 40500
298 500.00
3 years
27 875.00
Extreme 27875
298 500.00
5 years
5 680.56
Extreme 5680.5556
298 500.00
10 years
2 875.00
Extreme 2875
298 500.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 69 08-05-12
Director of Finance/CFO 58 20-05-31
Chief Tech/Sci/R&D Officer 58 -
Members of the board TitleAgeSince
Chief Executive Officer 69 08-05-12
Director/Board Member 59 21-03-28
Director/Board Member 68 21-03-28
More insiders
Date Price Change Volume
24-07-19 271,500 +3.23% 420,452
24-07-18 263,000 -4.01% 635,432
24-07-17 274,000 +0.37% 463,467
24-07-16 273,000 -1.97% 744,022
24-07-15 278,500 +2.20% 817,537

End-of-day quote Korea S.E., July 18, 2024

More quotes
Alteogen Inc. is a Korea-based company mainly engaged in the research and development of biopharmaceuticals. The Company operates biobetter business segment, which develops protein pharmaceuticals and cancer therapies, and bio similar business segment, which develops bio similar and animal medicines. The Company mainly provides growth hormone, herceptin, humira, antibodies, animal drugs and others.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
271,500 KRW
Average target price
246,667 KRW
Spread / Average Target
-9.15%
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. A196170 Stock